Market Movers

Thermo Fisher Scientific Inc.’s Stock Price Soars to $574.59, Marking an Impressive 4.78% Increase

Thermo Fisher Scientific Inc. (TMO)

574.59 USD +26.21 (+4.78%) Volume: 2.54M

Thermo Fisher Scientific Inc.’s stock price soared to $574.59, marking a significant rise of +4.78% this trading session, with a strong trading volume of 2.54M. This robust performance extends the company’s year-to-date gains to +8.25%, making TMO a promising stock for investors.


Latest developments on Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. is set to announce its financial results before the market opens on Wednesday, an event that could trigger significant stock price movements. The company has recently been in the news due to workforce disruptions, claiming rivals are poaching its employees. Moreover, Thermo Fisher’s involvement in various market sectors, such as 3D Cell Culture Models for Translational Medicine, Gene Delivery Technologies, and COVID-19 Vaccine Development Tools, all of which are experiencing new growth opportunities, could potentially influence its share price (NYSE:TMO).


Thermo Fisher Scientific Inc. on Smartkarma

Analysts on Smartkarma, like Baptista Research, are bullish on Thermo Fisher Scientific Inc. In their report titled “Thermo Fisher Scientific: 6 Major Factors Driving Its Growth In 2024! – Financial Forecasts”, they highlight the company’s strong execution and solid operational discipline in 2023. Thermo Fisher Scientific reported impressive numbers for that year, with a revenue of $42.9 billion, adjusted operating income of $9.81 billion, and adjusted earnings per share of $21.55. The company attributes these achievements to delivering differentiated short-term performance while also strengthening its long-term competitive position.


A look at Thermo Fisher Scientific Inc. Smart Scores

FactorScoreMagnitude
Value3
Dividend2
Growth3
Resilience2
Momentum4
OVERALL SMART SCORE2.8

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Thermo Fisher Scientific Inc, a company that manufactures scientific instruments and supplies, has received a mixed outlook based on the Smartkarma Smart Scores. While the company scored well in terms of momentum, indicating strong positive price trends, its scores for value, dividend, growth, and resilience were more moderate. This suggests that Thermo Fisher Scientific Inc may have solid short-term prospects but could face challenges in areas such as dividend payouts and overall growth.

Despite some mixed scores, Thermo Fisher Scientific Inc remains a key player in the scientific instruments and consumables industry. With a wide range of products and services catering to various sectors including pharmaceutical companies, research institutions, and government agencies, the company continues to be a reliable provider in the market. Investors may want to consider the company’s strong momentum score as a positive indicator for its future performance, while also keeping an eye on areas where improvements could potentially be made based on the Smartkarma Smart Scores.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars